Suzhou Sinovent Pharmaceutical

Sinovent is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to the discovery and development of innovative therapeutics for oncology, metabolic diseases, and autoimmune disorders. The company utilizes its proprietary drug discovery platforms to develop a robust pipeline of small molecules and biologics, including antibody-drug conjugates. Its lead candidate, XNW3009 (epetinadstat), is a highly potent URAT1 inhibitor currently in Phase 3 clinical trials for the treatment of gout. Sinovent maintains a global presence with operations in China, Australia, and the United States to facilitate international clinical development. The company has successfully raised significant venture capital from prominent investors to accelerate its diverse portfolio toward commercialization.